Allogeneic haematopoietic stem cell transplantation for myelofibrosis: A report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

British Journal of Haematology

Volumn 152, Issue 3, 2011, Pages 331-339

  Robin, Marie ^a   Tabrizi, Reza ^b   Mohty, Mohamad ^c   Furst, Sabine ^d   Michallet, Mauricette ^e   Bay, Jacques Olivier ^f   Cahn, Jean Yves ^g   De Coninck, Eric ^h   Dhedin, Nathalie ⁱ   Bernard, Marc ^j   Rio, Bernard ^k   Buzyn, Agnès ^l   Huynh, Anne ^m   Bilger, Karin ⁿ   Bordigoni, Pierre ^o   Contentin, Nathalie ^p   Porcher, Raphaël ^a   Socié, Gérard ^a   Milpied, Noel ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Team 12   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ DE FRANCHE COMTÉ   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j SERVICE DE RHUMATOLOGIE   (France)

^k HÔTEL DIEU   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m CHU PURPAN   (France)

ⁿ HÔPITAL DE HAUTEPIERRE   (France)

^o HÔPITAL D ENFANTS   (France)

^p Centre Hospitalier Becquerel   (France)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; Myelofibrosis

Indexed keywords

ANAGRELIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THALIDOMIDE; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; MYELOID METAPLASIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SIBLING; SPLENECTOMY; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; EPIDEMIOLOGIC METHODS; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; RECURRENCE; SPLENECTOMY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651334433     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08417.x     Document Type: Article

References (25)

1. Bacigalupo, A., Soraru, M., Dominietto, A., Pozzi, S., Geroldi, S., Van Lint, M.T., Ibatici, A., Raiola, A.M., Frassoni, F., De Stefano, F., Verdiani, S., Casarino, L. & Barosi, G. (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplantation, 45, 458-463.
2. Ballen, K.K., Shrestha, S., Sobocinski, K.A., Zhang, M.J., Bashey, A., Bolwell, B.J., Cervantes, F., Devine, S.M., Gale, R.P., Gupta, V., Hahn, T.E., Hogan, W.J., Kroger, N., Litzow, M.R., Marks, D.I., Maziarz, R.T., McCarthy, P.L., Schiller, G., Schouten, H.C., Roy, V., Wiernik, P.H., Horowitz, M.M., Giralt, S.A. & Arora, M. (2010) Outcome of transplantation for myelofibrosis. Biology Blood Marrow Transplantation, 16, 358-367.
3. Barosi, G., Ambrosetti, A., Centra, A., Falcone, A., Finelli, C., Foa, P., Grossi, A., Guarnone, R., Rupoli, S., Luciano, L., Petti, M.C., Pogliani, E., Russo, D., Ruggeri, M. & Quaglini, S. (1998) Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood, 91, 3630-3636.
4. Cervantes, F., Barosi, G., Demory, J.L., Reilly, J., Guarnone, R., Dupriez, B., Pereira, A. & Montserrat, E. (1998) Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 102, 684-690.
5. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.
6. Deeg, H.J., Gooley, T.A., Flowers, M.E., Sale, G.E., Slattery, J.T., Anasetti, C., Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R. & Appelbaum, F.R. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102, 3912-3918.
7. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013-1018.
8. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. & Thomas, E.D. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 18, 295-304.
9. Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., de Witte, T., Deeg, H.J. & Gluckman, E. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for blood and marrow transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 2831-2838.
10. Gupta, V., Kroger, N., Aschan, J., Xu, W., Leber, B., Dalley, C., Sabloff, M., Lipton, J.H., Messner, H. & Brune, M. (2009) A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplantation, 44, 317-320.
11. Kerbauy, D.M., Gooley, T.A., Sale, G.E., Flowers, M.E., Doney, K.C., Georges, G.E., Greene, J.E., Linenberger, M., Petersdorf, E., Sandmaier, B.M., Scott, B.L., Sorror, M., Stirewalt, D.L., Stewart, F.M., Witherspoon, R.P., Storb, R., Appelbaum, F.R. & Deeg, H.J. (2007) Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biology Blood Marrow Transplantation, 13, 355-365.
12. Kroger, N., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Stute, N., Fehse, N., Waschke, O., Fehse, B., Kvasnicka, H.M., Thiele, J. & Zander, A. (2005) Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British Journal of Haematology, 128, 690-697.
13. Kroger, N., Holler, E., Kobbe, G., Bornhauser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., Wandt, H., Burchert, A., Corradini, P., Schubert, J., Kaufmann, M., Dreger, P., Wulf, G.G., Einsele, H., Zabelina, T., Kvasnicka, H.M., Thiele, J., Brand, R., Zander, A.R., Niederwieser, D. & de Witte, T.M. (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 114, 5264-5270.
14. Lissandre, S., Bay, J., Cahn, J., Cacheux, V., Cabrespine, A., Guyotat, D., Cassinat, B., Peffault de Latour, R., Socié, G. & Robin, M. (2010) Allogeneic hematopoietic stem cell transplantation (HSCT) as a curative therapy in primary and secondary myelofibrosis (MF): a 14-year period oligocentric French experience. Bone Marrow Transplantation, in press.
15. Mesa, R.A., Silverstein, M.N., Jacobsen, S.J., Wollan, P.C. & Tefferi, A. (1999) Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. American Journal of Hematology, 61, 10-15.
16. Mesa, R.A., Li, C.Y., Ketterling, R.P., Schroeder, G.S., Knudson, R.A. & Tefferi, A. (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood, 105, 973-977.
17. Mesa, R.A., Nagorney, D.S., Schwager, S., Allred, J. & Tefferi, A. (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer, 107, 361-370.
18. Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703-1708.
19. Patriarca, F., Bacigalupo, A., Sperotto, A., Isola, M., Soldano, F., Bruno, B., van Lint, M.T., Iori, A.P., Santarone, S., Porretto, F., Pioltelli, P., Visani, G., Iacopino, P., Fanin, R. & Bosi, A. (2008) Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica, 93, 1514-1522.
20. Prentice, R.L., Kalbfleisch, J.D., Peterson, Jr, A.V., Flournoy, N., Farewell, V.T. & Breslow, N.E. (1978) The analysis of failure times in the presence of competing risks. Biometrics, 34, 541-554.
21. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825-828.
22. Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J.T., Popat, U., Alessandrino, E.P., Spivak, J.L., Smith, B.D., Klingemann, H.G., Fruchtman, S. & Hoffman, R. (2005) Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 105, 4115-4119.
23. Shulman, H.M., Sullivan, K.M., Weiden, P.L., McDonald, G.B., Striker, G.E., Sale, G.E., Hackman, R., Tsoi, M.S., Storb, R. & Thomas, E.D. (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. American Journal of Medicine, 69, 204-217.
24. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912-2919.
25. Tam, C.S., Kantarjian, H., Cortes, J., Lynn, A., Pierce, S., Zhou, L., Keating, M.J., Thomas, D.A. & Verstovsek, S. (2009) Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Journal of Clinical Oncology, 27, 5587-5593.